ABCL AbCellera Biologics Inc.
Healthcare$5.34+0.00%OpenMarket Cap: $1.63B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.68
P/S
20.05
EV/EBITDA
-9.45
DCF Value
$-1.92
FCF Yield
-11.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.1%
Operating Margin
-267.6%
Net Margin
-181.7%
ROE
-14.2%
ROA
-11.0%
ROIC
-13.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $8.3M | -4.1% | $-57.5M | $-43.2M | $— | — |
| Q4 null | $44.9M | 82.3% | $-28.6M | $-8.9M | $— | — |
| FY null | $75.1M | 61.6% | $-217.1M | $-146.4M | $— | — |
| Q3 null | $9.0M | 100.0% | $-76.3M | $-57.1M | $— | — |
| Q2 null | $17.1M | 100.0% | $-49.6M | $-34.7M | $— | — |
| Q1 null | $4.2M | 100.0% | $-62.7M | $-45.6M | $— | — |
| Q4 null | $5.0M | 100.0% | $-72.8M | $-34.2M | $— | — |
| FY null | $28.8M | 100.0% | $-314.8M | $-162.9M | $— | — |
| Q3 null | $6.5M | 100.0% | $-93.7M | $-51.1M | $— | — |
| Q2 null | $7.3M | 100.0% | $-93.5M | $-36.9M | $— | — |
| Q1 null | $10.0M | 100.0% | $-54.9M | $-40.6M | $— | — |
| Q4 2023 | $9.2M | 100.0% | $-66.1M | $-47.1M | $-0.16 | — |